China Medical System Holdings Limited announced that its subsidiary, Dermavon Holdings Limited, has had its Marketing Authorization Application for Comekibart Injection (MG-K10), a long-acting anti-IL-4Rα humanized monoclonal antibody injection, accepted by China's National Medical Products Administration (NMPA). The product is intended for the treatment of adults with moderate-to-severe atopic dermatitis. The announcement marks the beginning of the regulatory review process for this innovative drug in China. There is no indication that grant funding was obtained or that the regulatory review involves organizations other than China Medical System Holdings Limited and its subsidiaries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.